MD20140037A2 - Derivaţi de (4-fenilimidazol-2-il)etilamină utili ca modulatori ai canalului de sodiu - Google Patents

Derivaţi de (4-fenilimidazol-2-il)etilamină utili ca modulatori ai canalului de sodiu

Info

Publication number
MD20140037A2
MD20140037A2 MDA20140037A MD20140037A MD20140037A2 MD 20140037 A2 MD20140037 A2 MD 20140037A2 MD A20140037 A MDA20140037 A MD A20140037A MD 20140037 A MD20140037 A MD 20140037A MD 20140037 A2 MD20140037 A2 MD 20140037A2
Authority
MD
Moldova
Prior art keywords
phenylimidazol
sodium channel
derivatives useful
channel modulators
ethylamine derivatives
Prior art date
Application number
MDA20140037A
Other languages
English (en)
Romanian (ro)
Russian (ru)
Inventor
Шаранджит Каур Багал
Марк Ян Кемп
Дункан Чарльз Миллер
Йосихиса МУРАТА
Original Assignee
Pfizer Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47278356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MD20140037(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Limited filed Critical Pfizer Limited
Publication of MD20140037A2 publication Critical patent/MD20140037A2/ro

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MDA20140037A 2011-10-26 2012-10-15 Derivaţi de (4-fenilimidazol-2-il)etilamină utili ca modulatori ai canalului de sodiu MD20140037A2 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161551628P 2011-10-26 2011-10-26
PCT/IB2012/055610 WO2013061205A2 (fr) 2011-10-26 2012-10-15 Composés chimiques

Publications (1)

Publication Number Publication Date
MD20140037A2 true MD20140037A2 (ro) 2014-08-31

Family

ID=47278356

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20140037A MD20140037A2 (ro) 2011-10-26 2012-10-15 Derivaţi de (4-fenilimidazol-2-il)etilamină utili ca modulatori ai canalului de sodiu

Country Status (28)

Country Link
US (1) US9079878B2 (fr)
EP (1) EP2771335A2 (fr)
JP (1) JP5946538B2 (fr)
KR (1) KR101586966B1 (fr)
CN (1) CN103906746B (fr)
AP (1) AP2014007579A0 (fr)
AU (1) AU2012328034B2 (fr)
BR (1) BR112014009102A2 (fr)
CA (1) CA2850925C (fr)
CL (1) CL2014000956A1 (fr)
CO (1) CO6940427A2 (fr)
CR (1) CR20140185A (fr)
CU (1) CU20140046A7 (fr)
DO (1) DOP2014000085A (fr)
EA (1) EA023375B1 (fr)
EC (1) ECSP14013324A (fr)
GT (1) GT201400079A (fr)
HK (1) HK1198650A1 (fr)
IL (1) IL232267A (fr)
MD (1) MD20140037A2 (fr)
MX (1) MX337469B (fr)
NI (1) NI201400031A (fr)
PE (1) PE20141682A1 (fr)
SG (1) SG11201401032YA (fr)
TN (1) TN2014000147A1 (fr)
UA (1) UA109220C2 (fr)
WO (1) WO2013061205A2 (fr)
ZA (1) ZA201402281B (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013040479A1 (fr) * 2011-09-14 2013-03-21 Dow Agrosciences Llc Procédés et systèmes pour former des acides boroniques et produits intermédiaires de ceux-ci
NZ760006A (en) 2013-12-13 2022-07-29 Vertex Pharma Prodrugs of pyridone amides useful as modulators of sodium channels
KR102192572B1 (ko) 2014-06-09 2020-12-18 삼성전자주식회사 광원 모듈의 불량 검사방법, 광원 모듈의 제조 방법 및 광원 모듈 검사장치
JP6779217B2 (ja) * 2014-10-24 2020-11-04 アヴェクタス リミテッド 細胞原形質膜を越える送達方法
CN107613965A (zh) 2015-02-19 2018-01-19 普渡制药公司 用于减少胃排空的方法和组合物
IS2977B (is) 2015-02-23 2017-07-15 Actavis Group Ptc Ehf. Aðferð til framleiðslu á milliefnum sem eru nytsamleg við nýsmíði á elúxadólíni
EP3397760A2 (fr) 2015-12-30 2018-11-07 Avectas Limited Administration sans vecteur de protéines et de compositions d'édition de gènes dans des cellules et des tissus
JP7305534B2 (ja) 2016-07-06 2023-07-10 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛関連障害を処置するための物質及び方法
EP3481857A1 (fr) 2016-07-06 2019-05-15 Crispr Therapeutics AG Matériaux et méthodes de traitement de troubles liés à la douleur
UA124857C2 (uk) 2017-05-16 2021-12-01 Вертекс Фармасьютикалз Інкорпорейтед Дейтеровані піридонаміди і їх проліки як модулятори натрієвих каналів
PE20201164A1 (es) 2017-07-11 2020-10-28 Vertex Pharma Carboxamidas como moduladores de los canales de sodio
CN111918650A (zh) 2018-02-12 2020-11-10 沃泰克斯药物股份有限公司 治疗疼痛的方法
WO2020146612A1 (fr) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Esters et carbamates utilisés en tant que modulateurs de canaux sodiques
US20230062053A1 (en) 2019-01-10 2023-03-02 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
WO2020176763A1 (fr) 2019-02-27 2020-09-03 Vertex Pharmaceuticals Incorporated Forme posologique comprenant un promédicament inhibiteur de canal sodique na 1,8
WO2020219867A1 (fr) 2019-04-25 2020-10-29 Vertex Pharmaceuticals Incorporated Compositions de co-cristaux d'amide de pyridone pour le traitement de la douleur
US11834441B2 (en) 2019-12-06 2023-12-05 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofurans as modulators of sodium channels
CN117813302A (zh) 2021-06-04 2024-04-02 沃泰克斯药物股份有限公司 经取代的四氢呋喃-2-甲酰胺作为钠通道调节剂
EP4347031A1 (fr) 2021-06-04 2024-04-10 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hétéro)aryl) tétrahydrofuran carboxamides utilisés en tant que modulateurs de canaux sodiques
AU2022285758A1 (en) 2021-06-04 2023-11-30 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran analogs as modulators of sodium channels
WO2022256708A1 (fr) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Formes galéniques solides et schémas posologiques comprenant du (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-méthoxy-phényl)-4,5-diméthyl-5-(trifluorométhyl)tétrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide
JP2024520643A (ja) 2021-06-04 2024-05-24 バーテックス ファーマシューティカルズ インコーポレイテッド ナトリウムチャネルの調節因子としてのヒドロキシ及び(ハロ)アルコキシ置換テトラヒドロフラン
EP4347584A1 (fr) 2021-06-04 2024-04-10 Vertex Pharmaceuticals Incorporated Analogues de n-(hydroxyalkyl(hétéro)aryl)tétrahydrofurane carboxamide en tant que modulateurs de canaux sodiques
WO2023205468A1 (fr) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Composés hétéroaryle pour le traitement de la douleur
WO2023205465A1 (fr) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Composés hétéroaryles pour le traitement de la douleur
US20230373925A1 (en) 2022-04-22 2023-11-23 Vertex Pharma Heteroaryl compounds for the treatment of pain
US20230382910A1 (en) 2022-04-22 2023-11-30 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2023211990A1 (fr) 2022-04-25 2023-11-02 Siteone Therapeutics, Inc. Inhibiteurs d'amides hétérocycliques bicycliques de na v1.8 pour le traitement de la douleur

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (fr) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing-gum contenant des agents medicamenteux actifs
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US7291641B2 (en) * 1999-10-11 2007-11-06 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
TWI292316B (en) * 1999-10-11 2008-01-11 Sod Conseils Rech Applic Pharmaceutical composition of thiazole derivatives intended to inhibit mao and/or lipidic peroxidation and/or to act as modulators of sodium channels and the use thereof
US7112366B2 (en) 2001-01-05 2006-09-26 The Ohio State University Chemical monolayer and micro-electronic junctions and devices containing same
TWI248438B (en) * 2001-04-10 2006-02-01 Sod Conseils Rech Applic Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
FR2842808B1 (fr) * 2002-07-25 2004-09-10 Sod Conseils Rech Applic Nouveaux derives d'arylimidazoles, leur preparation et leurs applications therapeutiques
RS51403B (en) * 2004-05-07 2011-02-28 Warner-Lambert Company Llc DERIVATIVES OF 3-OR 4-MONOSUBSTITIZED PHENOLS AND THIOPHENOLS USEFUL AS H3 LIGANDS
US7456164B2 (en) * 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
US7786291B2 (en) 2004-10-27 2010-08-31 Schering Corporation Compositions and methods for short interfering nucleic acid inhibition of Nav1.8
KR101380137B1 (ko) * 2005-12-22 2014-04-11 뉴론 파마슈티칼즈 에스. 피. 에이. 칼슘 및/또는 나트륨 채널 조절제로서 2-페닐에틸아미노유도체
GEP20125425B (en) 2006-10-18 2012-03-26 Pfizer Prod Inc Biaryl ether urea compounds
ATE461177T1 (de) 2007-03-23 2010-04-15 Icagen Inc Ionenkanal-hemmer
CN101675040A (zh) 2007-05-03 2010-03-17 辉瑞有限公司 作为钠通道调节剂的2-吡啶甲酰胺衍生物
CA2685952C (fr) * 2007-05-03 2012-03-13 Pfizer Limited Derives de pyrazine
WO2009012242A2 (fr) 2007-07-13 2009-01-22 Icagen, Inc. Inhibiteurs des canaux sodiques

Also Published As

Publication number Publication date
NZ623090A (en) 2015-10-30
AU2012328034A1 (en) 2014-05-15
EA201490864A1 (ru) 2014-08-29
NI201400031A (es) 2014-10-01
SG11201401032YA (en) 2014-07-30
MX337469B (es) 2016-03-02
EP2771335A2 (fr) 2014-09-03
CN103906746B (zh) 2015-12-09
WO2013061205A8 (fr) 2014-03-27
BR112014009102A2 (pt) 2017-04-18
IL232267A (en) 2016-10-31
CA2850925A1 (fr) 2013-05-02
CL2014000956A1 (es) 2014-07-18
ZA201402281B (en) 2015-11-25
JP5946538B2 (ja) 2016-07-06
JP2014530900A (ja) 2014-11-20
ECSP14013324A (es) 2014-05-31
IL232267A0 (en) 2014-06-30
AP2014007579A0 (en) 2014-04-30
CA2850925C (fr) 2017-01-10
GT201400079A (es) 2015-06-02
MX2014004738A (es) 2014-08-01
DOP2014000085A (es) 2014-08-31
HK1198650A1 (en) 2015-05-22
KR20140069234A (ko) 2014-06-09
KR101586966B1 (ko) 2016-01-19
US20140296313A1 (en) 2014-10-02
US9079878B2 (en) 2015-07-14
WO2013061205A2 (fr) 2013-05-02
CU20140046A7 (es) 2014-10-02
TN2014000147A1 (fr) 2015-09-30
UA109220C2 (uk) 2015-07-27
PE20141682A1 (es) 2014-11-14
AU2012328034B2 (en) 2015-04-23
CO6940427A2 (es) 2014-05-09
CN103906746A (zh) 2014-07-02
WO2013061205A3 (fr) 2013-06-27
EA023375B1 (ru) 2016-05-31
CR20140185A (es) 2014-06-03

Similar Documents

Publication Publication Date Title
MD20140037A2 (ro) Derivaţi de (4-fenilimidazol-2-il)etilamină utili ca modulatori ai canalului de sodiu
WO2012007877A3 (fr) Composés chimiques
MX2021006421A (es) Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17).
WO2012007869A3 (fr) Composés chimiques
PH12016501028A1 (en) Prodrugs of pyridone amides useful as modulators of sodium channels
CR20200157A (es) Moduladores de la proteína reguladora de conductancia transmembrana de la fibrosis quística y métodos de uso
MX2009011816A (es) Derivados de piridina.
WO2012007868A3 (fr) Composés chimiques
MX359882B (es) Amidas como moduladores de canales de sodio.
MX2015003653A (es) Derivados de amida del acido benzoimidazol-carboxilico como moduladores del receptor apj.
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
UY32156A (es) Derivados sustituidos de la n2 - [1-(5 - fluoropirimidin -2-il) etil] - n4 - (1-metil - 1h-imidazol - 4 - il)) - pirimidina - 2,4 - diaminas y sus sales farmacéuticamente aceptables, proceso de preparación, composiciones conteniéndolos y aplicaciones.
UA104489C2 (uk) Сполуки для лікування дисліпідемії та споріднених хвороб
AU2012258977A8 (en) Inhibitors of LRRK2 kinase activity
MY181928A (en) Sodium channel modulators for the treatment of pain and diabetes
IN2014CN04530A (fr)
MY148948A (en) Catecholamine derivatives and prodrugs thereof
MD20160053A2 (ro) Derivaţi ai purinei 2,6-substituite şi utilizarea acestora în tratamentul tulburărilor proliferative
CA2912921C (fr) Composes de pyrazole a titre de modulateurs de fshr et leurs utilisations
GEP20166483B (en) Phenyl-3-aza-bicyclo[3.1.0] hex-3-yl-methanones and the use thereof as medicament
MY183111A (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
MD20160105A2 (ro) 2-Amino-6-metil-4,4a,5,6-tetrahidropirano[3,4-d][1,3]tiazin-8a(8H)-il-1,3-tiazol-4-il amide
PH12015502632A1 (en) Cxcr7 receptor modulators
PH12014501943A1 (en) Novel compounds for the treatment of dyslipidemia and related diseases
PH12017501876A1 (en) Pyridopyrimidones and their use as nmda receptor modulators

Legal Events

Date Code Title Description
FA9A Abandonment or withdrawal of application (patent for invention)